ANI PHARMS
GenericsANI PHARMS is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology.
ANI PHARMS's Key Drugs
ANI PHARMS's core commercial portfolio centers on LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED), MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
ANI PHARMS's Recent FDA Approvals
ANI PHARMS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
ANI PHARMS's Therapeutic Areas
ANI PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 14 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ANI PHARMS's Top Competitors
ANI PHARMS's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ANI PHARMS Pipeline Snapshot
Active clinical trials for ANI PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (2)
Company Info
- First Approval
- 1952-01-21
- Latest
- 2026-06-18
- Applications
- 251